India’s Lupin seeks biosimilar, lung drug partners
MUMBAI (Reuters) - Indian drugmaker Lupin Ltd is seeking new partnership agreements as it moves into the promising fields of inhaled lung drugs and copies of biotechnology drugs, its managing...
Home > Reviews
All Stories
Emerging market policymakers move to allay currency concerns
DAVOS/LONDON (Reuters) - Top emerging market policymakers moved to allay concerns about their economies on Friday after investors sold off their currencies, raising fears of a broad market rout. The...
Analysis: Davos bosses tread warily in rocky emerging markets
DAVOS, Switzerland (Reuters) - Multinational companies are becoming more picky about emerging market investments as slowing growth in upstart economies and a recovery in the West takes the shine off...
GlaxoSmithKline to stop paying doctors to promote drugs
LONDON (Reuters) - GlaxoSmithKline said on Tuesday it would stop paying doctors to promote its products through speaking engagements and end linking compensation for its sales representatives to the number...
GlaxoSmithKline to stop paying doctors to promote drugs
LONDON (Reuters) - GlaxoSmithKline said on Tuesday it would stop paying doctors to promote its products through speaking engagements and end linking compensation for its sales representatives to the number...
Suntory closing in on deal to buy GSK drinks brands: sources
LONDON (Reuters) - Japan's Suntory Beverage & Food Ltd is in advanced talks to buy the Lucozade and Ribena brands from GlaxoSmithKline for more than 1 billion pounds ($1.6 billion)...
Amgen, Cytokinetics heart failure drug misses goal in study
AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Despite...
Amgen, Cytokinetics heart failure drug misses goal in study
AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Despite...
Novartis heart failure drug effective across patient groups
AMSTERDAM (Reuters) - An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial...
Doctors get good and bad safety news on diabetes drugs
AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might...